Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 196

1.

A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.

Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schömig A; ISAR-SMART-2 Investigators.

J Intern Med. 2004 Nov;256(5):388-97.

PMID:
15485474
[PubMed - indexed for MEDLINE]
3.

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.

Circulation. 2004 Dec 14;110(24):3627-35. Epub 2004 Nov 7.

PMID:
15531766
[PubMed - indexed for MEDLINE]
Free Article
4.

A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.

Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AW, Lee MK, Li SK, Ng W, Lee PY, Lam KF, Tse HF, Lau CP.

J Invasive Cardiol. 2005 Oct;17(10):534-8.

PMID:
16204748
[PubMed - indexed for MEDLINE]
5.

Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.

Rodriguez A, Rodríguez Alemparte M, Fernández Pereira C, Sampaolesi A, da Rocha Loures Bueno R, Vigo F, Obregón A, Palacios IF; LASMAL investigators.

Am J Med. 2005 Jul;118(7):743-51.

PMID:
15989908
[PubMed - indexed for MEDLINE]
6.

Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.

Giri S, Mitchel JF, Hirst JA, McKay RG, Azar RR, Mennett R, Waters DD, Kiernan FJ.

Am J Cardiol. 2000 Aug 1;86(3):269-74.

PMID:
10922431
[PubMed - indexed for MEDLINE]
7.

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.

Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators.

JAMA. 2005 May 4;293(17):2109-17.

PMID:
15870414
[PubMed - indexed for MEDLINE]
8.
9.

Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.

Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ.

Circulation. 2000 Jul 4;102(1):28-34.

PMID:
10880411
[PubMed - indexed for MEDLINE]
Free Article
10.

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.

Schömig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Berger PB, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators.

Eur Heart J. 2005 Jul;26(14):1379-84. Epub 2005 Feb 25.

PMID:
15734767
[PubMed - indexed for MEDLINE]
Free Article
11.

Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.

Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R; CADILLAC Investigators.

J Am Coll Cardiol. 2003 Sep 17;42(6):971-7.

PMID:
13678914
[PubMed - indexed for MEDLINE]
Free Article
12.

Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.

Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A; ISAR-DESIRE Study Investigators.

JAMA. 2005 Jan 12;293(2):165-71.

PMID:
15644543
[PubMed - indexed for MEDLINE]
13.

Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.

Iijima R, Ndrepepa G, Mehilli J, Dirschinger J, Pache J, Seyfarth M, Schömig A, Kastrati A.

Am J Cardiol. 2008 May 1;101(9):1226-31. doi: 10.1016/j.amjcard.2007.12.019. Epub 2008 Mar 5.

PMID:
18435948
[PubMed - indexed for MEDLINE]
14.

Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.

van den Brand M, Laarman GJ, Steg PG, De Scheerder I, Heyndrickx G, Beatt K, Kootstra J, Simoons ML.

Eur Heart J. 1999 Nov;20(21):1572-8.

PMID:
10529325
[PubMed - indexed for MEDLINE]
Free Article
15.

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.

Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ.

Circulation. 1999 Dec 21-28;100(25):2477-84.

PMID:
10604884
[PubMed - indexed for MEDLINE]
Free Article
16.

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.

JAMA. 1997 Aug 13;278(6):479-84.

PMID:
9256222
[PubMed - indexed for MEDLINE]
17.

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.

JAMA. 2008 Apr 16;299(15):1788-99. doi: 10.1001/jama.299.15.joc80026. Epub 2008 Mar 30.

PMID:
18375998
[PubMed - indexed for MEDLINE]
18.

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators.

Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.

PMID:
12939213
[PubMed - indexed for MEDLINE]
Free Article
19.

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.

N Engl J Med. 1999 Jul 29;341(5):319-27.

PMID:
10423466
[PubMed - indexed for MEDLINE]
Free Article
20.

Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.

Bagur R, Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Nguyen CM, Noel B, Larochellière RD, Poirier P, Costerousse O, Roy L.

Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1010-6. doi: 10.1002/ccd.22235.

PMID:
19753635
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk